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Cancer imposes a heavy societal burden worldwide, in terms of 
both epidemiology and costs. The introduction of more sophisti-
cated imaging and diagnostic techniques and advanced drugs that 
specifically target tumor cells is leading to increasingly expensive 
treatments, which may be affordable only for few patients. Pre-
vention, and particularly primary prevention, is an effective way 
of addressing the challenging issue of cancer, since between a 
third and a half of cancers could be prevented on the basis of 
our current knowledge of risk factors. Moreover, prevention is 
cost-effective, its effects are not limited to high-risk subjects but 
extend to the entire population, and it is not dependent on socio-
economic status. Regulatory measures can have a broad impact, 
even on future generations; by empowering and educating sub-
jects, promoting healthy behaviours and teaching self-care, they 
can trigger a virtuous cycle. In recent decades, oncology has 
shifted from being merely reactive to being proactive; this shift 
has led to the development of so-called “P4 medicine”, where the 
4 Ps stand for “preventive”, “predictive”, “personalized” and 
“participatory”. Prevention programs are an important part of 
the effort to control cancer, as they are able to reduce both the 
incidence of cancer and mortality. For instance, screening for 
colorectal, breast and cervical cancer is reducing the burden of 
these common tumors. Anti-cancer vaccines, both prophylactic 
and therapeutic, constitute another important preventive tool. 
Although progress has been made in these areas, much remains 
to be done. With regard to screening programs, coverage could 
be increased by introducing new, more acceptable, less invasive 
tests, stratifying screening through correlation with anamnestic, 
clinical, radiological and genomic data (so-called “population-
based personalized cancer screening”), and exploiting new infor-
mation and communication technologies, such as smartphone 
applications or personalized text messages (so-called “screening 
2.0”). Advocacy and recommendations by physicians can also 
play a role, in that eligible subjects need to be able to discuss 
their doubts and their perceived psycho-social barriers. How-
ever, new screening initiatives should be implemented only after a 
careful health technology assessment has been performed within 
the framework of evidence-based medicine, organized screening 
programs have been strengthened and opportunistic or spontane-
ous programs have been limited.
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Summary
The global burden of cancer
Cancer imposes a heavy societal burden worldwide, in 
terms of both epidemiology and costs  [1,  2]. Despite 
striking advances in the field of molecular oncology, 
combating cancer remains a challenge. The introduc-
tion of more sophisticated imaging and diagnostic tech-
niques and advanced drugs that specifically target tumor 
cells (so-called individualized drug therapy) is driving 
up the costs of treatment [2, 3]. As a consequence, the 
benefit of these achievements may be scarcely afford-
able and the costs could dramatically impact on health-
care systems [2, 3]. Despite its alleged advantages, the 
implementation of genomics in routine clinical practice 
remains far from cost-effective [3].
As Vineis and Wild maintain [1], prevention, and spe-
cifically primary prevention, is a particularly effective 
way to address the challenging issue of cancer.
Primary and secondary prevention offers several advan-
tages:
1. As such programs are population-based, they could 
benefit people other than those directly targeted [1].
2. As cancer has a long latency period, its causes and 
risk factors could be eliminated or reduced in the 
long term, thus yielding a broader impact on Pub-
lic Health. Interventions are not limited to surgical 
or pharmacological treatments, but include a variety 
of programs and measures aimed at correcting un-
healthy lifestyles and favouring continuous trans-
formation, for example through regulation against 
occupational or environmental exposure to certain 
substances. By empowering and educating people, 
promoting healthy behaviors and teaching self care, 
a virtuous cycle can be set in motion, meaning that 
these preventive efforts do not need to be renewed 
with every generation. This is important in periods 
of economic and financial hardship, when public 
resources are scarce  [1]. Moreover, some regula-
tory measures could help to prevent various types of 
cancer and other pathologies; for example, cigarette 
smoking, besides being associated with lung cancer, 
could lead to an increased risk of developing breast 
cancer  [4], prostate cancer  [5], lymphoma  [6] and 
other diseases [7]. In addition, avoiding exposure to 
I. Valle et al.
E22
carcinogenic substances may contribute to prevent-
ing other non-communicable diseases (NCDs), such 
as cardiovascular, reproductive, endocrine and dys-
metabolic pathologies  [1]. In conclusion, a single 
public health measure would have multiple, enduring 
“cascade effects” which a single clinical intervention 
would not have.
3) Prevention is cost-effective and can impact positive-
ly on socio-economic inequalities  [8-12]. Since up 
to half of cancers could be prevented on the basis of 
present knowledge of etiopathogenesis and risk fac-
tors [1], preventive medicine can act as a rapid and 
effective means of connecting research with clinical 
practice [13].
Primary and secondary prevention should therefore be 
regarded as a priority for global cancer control [1, 14].
Oncology in the framework of P4 
medicine
In recent decades, oncology has shifted from being 
merely reactive and has adopted a proactive model with-
in the framework of so-called “P4 medicine” [15, 16], 
where the 4 Ps stand for predictive, preventive, person-
alized and participatory. Advances in the field of molec-
ular biology, high-throughput technologies (HTTs) and 
“omics” sciences, as well as in imaging techniques and 
mathematical and computational modelling, have led to 
the discovery of biomarkers which can be used to pre-
dict the onset, course and prognosis of tumors; this ena-
bles diagnosis, treatment and prevention to be correlated 
within a highly integrated, coherent framework. Rather 
than being “one-size-fits-all”, P4 medicine is individu-
ally tailored to the specific needs of the patient. Screen-
ing and prevention play a major role in an approach that 
is gradually shifting from disease to wellness.
It should be emphasized that this new effort requires 
a holistic view at all levels  [17]; cancer is a complex 
adaptive system (CAS), the etiopathogenesis of which 
can be unravelled only by means of a systems approach 
(systems biology and “omics” sciences). Cancer man-
agement requires multi-level system-based manage-
ment [18]. Organized screening is a highly standardized 
form of “systems screening”; as it is constantly moni-
tored through quality check and process indicators and 
relies on evidence-based protocols and guidelines, it dif-
fers from opportunistic or spontaneous screening [19].
In the system of systems (SoSs) perspective, cancer 
screening programs can be integrated into health pro-
motion plans, becoming “teachable moments”, during 
which people can be sensitized to the importance of 
proper nutrition, physical activity and other healthy be-
haviors [20]. In this way, as already mentioned, a virtu-
ous cycle with cascade effects can be set in motion.
The following sections present an overview of the cur-
rently available organized cancer screening tests, a dis-
cussion of their present state and future prospects, and a 
brief look at the topic of anti-cancer vaccines.
Prevention of cervical cancer
Cervical cancer is the tenth most frequent cancer and the 
third most common cancer in terms of mortality, after 
breast and colorectal cancer  [21-23], though this trend 
is decreasing.
Risk factors for developing cervical cancer include: to-
bacco and alcohol consumption, a history of genital warts, 
early age on first sexual intercourse or first pregnancy, 
multiparity, sexual promiscuity and unprotected sex, a 
history of sexually transmitted diseases (STDs), low so-
cio-economic status and low educational level, Human 
Immunodeficiency Virus (HIV) infection and other con-
ditions resulting in immunosuppression [21-23].
Screening modalities include  [21-23]: 1)  cervical cytol-
ogy (Papanicolau or Pap smear), which may be conven-
tional or liquid-based (LBC), and may be assisted by au-
tomated screening technologies (ASTs)  [24]; 2) colpos-
copy, which involves direct visual inspection (DVI) per-
formed by using 3-5% acetic acid (VIA), 3-5% acetic acid 
and magnification (VIAM), or Lugol’s iodine (VILI); and 
3) HPV-DNA testing [25]. Other modalities, such as cer-
vicoscopy, cervicography, colpohysteroscopy/microcol-
pohysteroscopy, speculoscopy (a magnified chemilumi-
nescent screening examination) and polar probes (such 
as spectrophotometry/microspectrophotometry, Raman 
scattering and fluorescence spectroscopy), are still ex-
perimental and can be used as second-line techniques for 
the further evaluation and assessment of abnormal results.
A next-generation assay, which is quite promising, is 
HPV mRNA testing [26-28].
According to the 2010 European Guidelines for Qual-
ity Assurance of Cervical Cancer Screening  [29], the 
American Cancer Society (ACS), the American College 
of Obstetricians and Gynaecologists (ACOG) and the 
Centers for Disease Control and Prevention-Advisory 
Committee on Immunization Practices (CDC-ACIP), 
the age at which screening should be started is in the 
range of 20-30 years, but preferably not before 25 years 
(in Italy, for example, the age is 25 years). Women aged 
21-29 years should undergo a Pap smear every 3 years, 
regardless of their sexual activity. If the result of the 
test is abnormal (such as atypical cells of undetermined 
significance, or ASCUS), the woman should undergo 
HPV-DNA testing [29, 30]. Women over the age of 29 
years can be screened every 5 years with a combination 
of HPV-DNA testing and Pap smear. The age at which 
screening should be discontinued is in the range of 60-
65 years of age (in Italy, for example, it is 65 years), in 
the absence of abnormal results [29, 30].
Recently, four European randomized controlled trials 
(RCTs) (Swedescreen in Sweden, POBASCAM in the 
Netherlands, ARTISTIC in Great Britain and NTCC in 
Italy) have shown that HPV-based screening started at 
the age of 30 years, with screening intervals of up to 5 
years, is still effective in protecting women against in-
vasive carcinoma [31]. However, although this strategy 
appears to be the most cost-effective, it is applied in few 
countries [32].
Compliance with cervical cancer screening programs 
is still unsatisfactory and strongly age-dependent  [33]. 
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Variables which can predict adherence to screening in-
clude educational level, culture, psychosocial issues and 
marital status [33, 34].
High-quality cervical screening helps to reduce the inci-
dence of cervical cancer and mortality. In Italy, the in-
cidence of squamous cell and invasive cancers has sig-
nificantly decreased from 11.6/100,000 to 8.7/100,000 
since the introduction of cervical screening [35].
Prevention of colorectal cancer
Colorectal cancer (CRC) is the third most common can-
cer in men, after lung and prostate cancer, and the sec-
ond most frequent cancer in women after breast cancer, 
with more than 1,360,000 cases per year (10% of the 
total cancer burden). Its incidence increases with age, 
and more men than women are affected [36]. CRC is a 
major cause of cancer-related death, ranking fourth after 
lung, liver and stomach cancer [37].
Risk factors for developing CRC are: obesity [38], con-
sumption of red and highly processed meat [39], tobacco 
and alcohol use, a history of inflammatory bowel disease 
(IBD) such as ulcerative colitis and Crohn’s disease, a 
family history of inherited CRC, and syndromes such 
as familial adenomatous polyposis (FAP) or hereditary 
nonpolyposis colorectal cancer (HNPCC) [40]. Vegeta-
ble consumption and physical activity are protective fac-
tors [41].
CRC can be screened in several ways [42, 43], the most 
commonly used method being the stool test, known as 
fecal occult blood test (FOBT). Variants of this test are 
the guaiac-based FOBT (gFOBT), the fecal immuno-
chemical test (FIT) and the stool DNA test (sDNA).
In the event of positivity, flexible sigmoidoscopy (FS) or 
total colonoscopy (TC) can be performed [37]. Comput-
ed tomography (CT) scans (CT colonography, or CTC) 
can be used in those patients in whom TC is contraindi-
cated or if it has not been possible to perform a complete 
TC [37].
Other tests, which are still experimental, are double-con-
trast barium enema (DCBE), colon capsule endoscopy 
(CCE) and high-resolution colonoscopy (HRC)  [37]. 
The Epi proColon® 2.0 test (Epigenomics AG) is a high-
ly sensitive and specific new-generation test; this as-
sesses aberrant methylated patterns of the septin 9 gene, 
which is usually hypermethylated in CRC [44].
CRC screening should be started at the age of 50 years; 
subjects who are particularly at risk for CRC should be 
screened earlier and more frequently. According to the 
guidelines, screening options for eligible subjects in-
clude: FOBT every year; DCBE every 5 years; FS every 
5 to 10 years, usually combined with FOBT every 1-3 
years; virtual colonoscopy (VC) every 5 years; colonos-
copy every 10 years. In the event of positivity, colonos-
copy should be performed [37].
Adherence to the program is still low: for example, a 
recently published systematic review has found that in 
2000, in the USA, only 34% of the population complied 
with CRC screening following the recommendations 
and guidelines  [45]. It has been observed that doctors, 
particularly family doctors, play a major role in increas-
ing participation by discussing the benefits and useful-
ness of screening with their patients [46, 47].
High-quality CRC screening  [48] has been seen to re-
duce the incidence of CRC by 33% and mortality due to 
CRC by 43% [36].
Prevention of breast cancer
Despite advances in treatment and diagnosis, breast can-
cer is still a serious Public Health concern  [49], with 
1,384,155 expected new cases worldwide and an esti-
mated 459,000 deaths  [49]. Moreover, both incidence 
and related mortality have increased by 18% since 2008. 
According to the ACS, breast cancer affects one in every 
eight women in the US. It is estimated that the annual 
global burden of breast cancer will reach 3.2 million 
new cases by 2050 [49].
Risk factors for developing a breast cancer include: 
breast size  [50], lack of physical activity, overweight 
and obesity [51-53], infertility and nulliparity, first full-
term pregnancy at the age of 30 years or later, early age 
on menarche, tobacco and alcohol use, hormone replace-
ment therapy (HRT) such as oestrogen and progestin, 
exposure to diethylstilbestrol (DES), inherited genetic 
anomalies (BRCA1, BRCA2) [49, 53, 54], and Cowden 
and Li-Fraumeni syndrome [53, 54]. Breastfeeding and 
vegetable consumption are protective factors.
Mammography is the gold standard in early breast can-
cer detection; screening results are communicated by 
means of the highly standardized “breast imaging re-
porting and database system” (BI-RADS).
In 2009-2010, the US Preventive Services Task Force 
(USPSTF) issued new updated recommendations for rou-
tine mammography screening, after examining and com-
paratively assessing five different screening modalities: 
namely, screen-film two-dimensional (2D) mammogra-
phy, clinical breast examination (CBE), breast self-exam-
ination (BSE), three-dimensional (3D) digital mammog-
raphy (such as the Digital Breast Tomosynthesis, or DBT, 
recently approved by the Food and Drug Administration, 
FDA), and magnetic resonance imaging (MRI) [55]. Oth-
er screening modalities, such as thermography, are still 
experimental, while tissue-sampling approaches (fine-
needle aspiration, or FNA, nipple aspiration or ductal lav-
age) are usually used for diagnostic purposes only. The 
USPSTF recommended against routine mammographic 
screening in women aged 40-49 years, unless the pa-
tient’s history suggested it and after careful assessment of 
the benefits and harm. Biennial mammographic screen-
ing was recommended for women aged 50-74 years; no 
evidence of additional benefits or harms emerged with 
regard to CBE, while BSE was advised against. The USP-
STF called for further studies on the clinical usefulness of 
digital mammography and MRI.
By contrast, the American College of Radiology (ACR), 
the American Society of Clinical Oncology (ASCO) 
and the Society of Breast Imaging (SBI) calculated that 
mammography, if not performed in women aged 40-49 
years, would miss 19-33% of cancers and would sacri-
fice 33 years of life per 1,000 women screened. These 
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agencies therefore recommended routine screening 
mammography commencing at the age of 40 years.
A mathematical model seems to support the opinion 
of the USPSTF  [56], since including women in their 
40s would increase the number of false-positive cases 
by 53%. One solution could be the use of ultrasonog-
raphy  [57], which would enable radiologists to de-
tect additional 3-4 cancers per 1,000 high-risk women 
screened [48]. Moreover, MRI and ultrasound as supple-
mental screening techniques would be particularly use-
ful for women with extremely dense breasts [48]. How-
ever, implementation of this policy should be carefully 
evaluated by means of a cost-effectiveness analysis, in 
order to develop the best strategy.
Despite these controversies, breast cancer screening has 
undoubtedly contributed to reducing cancer mortality by 
30-50% [58]. In Italy, after the introduction of organized 
mammography screening, the IMPACT working group 
found a statistically significant, steady reduction in the 
incidence of late-stage breast cancer from the third year 
onward, with the incidence rate ratio (IRR) declining 
from 0.81 to 0.71 [59]. This decline was more evident 
in three regions: Liguria, Tuscany and Lombardy [60]. 
However, coverage remains low (69.1%) [61].
Anti-cancer vaccines
There are two kinds of anti-cancer vaccines: preventive 
(or prophylactic) and therapeutic vaccines. The former 
include anti-HPV vaccines (Gardasil® and Cervarix®) 
for the prevention of cervical cancer  [62, 63], and an-
ti-HBV vaccines for the prevention of hepatocellular 
carcinoma [64]. The latter are whole cell-, protein- and 
peptide-, dendritic cell-, gene-, or idiotype immunoglob-
ulin-based vaccines [65].
Generally speaking, anti-cancer vaccines stimulate cy-
totoxic T lymphocytes (CTL) against tumor-associated 
antigens (TAA) or tumor-specific antigens (TSAs). 
Therapeutic anti-cancer vaccines have greatly benefited 
from forward vaccinology [66, 67], which uses advanced 
mass spectrometry (MS) approaches, thus enabling the 
design of customized vaccines. Currently, Oncophage® 
and Provenge® represent the two most successful ap-
proved anti-cancer vaccines.
The autologous heat shock protein (HSP)-based vaccine 
Oncophage® (HSP-peptide complex 96, HSPPC-96) 
was released in May 2008 in Russia for the treatment 
of kidney cancer patients at intermediate risk of dis-
ease recurrence. Clinical trials conducted among meta-
static kidney cancer patients had shown a statistically 
significant improvement  [68]. The second-generation 
autologous HSP-based vaccine, Vitespen®, a purified 
gp96-peptide complex, has yielded promising results in 
a variety of cancers, including CRC, glioblastoma, lung 
cancer, melanoma and renal cell carcinoma [69].
In April 2010, the FDA approved Sipuleucel-T 
(Provenge®, Dendreon) for metastatic prostate can-
cer [70]. This vaccine, which elicits CTLs against pros-
tatic acid phosphatase (PAP), is obtained by using leuka-
pheresis, isolating APCs and processing them with PAP 
crosslinked to the granulocyte-macrophage colony-stim-
ulating factor (GM-CSF).
Other approved cancer vaccines are Nivolumab (Opdi-
vo®, formerly known as MDX-1106, recently approved 
for melanoma and squamous non-small cell lung can-
cer, currently under clinical trial for further malignan-
cies, including CRC and brain cancer), Ipilimumab (Ye-
rvoy®, approved for melanoma, under trial for bladder 
and prostate cancer) and Gendicine® (approved by the 
Chinese State Food and Drug Administration or CSFDA 
for the head and neck squamous cell carcinoma).
Cancer vaccines currently under clinical trial include 
Tremelimumab (also known as Ticilimumab or CP-
675,206, under trial for mesothelioma, bladder cancer), 
DCvax® (for astrocytoma), BiovaxIDTM (Dasiprotimut-
T, under trial for follicular lymphoma), ProstVac-VF®/
TricomTM (under trial for prostate cancer), PanVac-VFTM 
(a poxviral-based cancer vaccine containing transgenes 
for the epithelial mucin 1 and carcinoembryonic antigen 
or CEA, currently under clinical trial for a variety of 
cancers, including breast and pancreatic tumor), MVax® 
(under trial for melanoma), OncoVax® (under trial for 
CRC), Reniale® (under trial for renal cancer) and a gly-
coprotein-100 (gp100)-based vaccine against melano-
ma [65, 68], among others.
Future screening programs
In many countries, screening tests are also performed 
for lung cancer, melanoma, prostatic, oral, pancreatic 
and ovarian cancers. However, their unstructured ap-
plication has resulted in poor or insufficient scientific 
evidence  [71]. For example, clinical trials such as the 
European Randomized Study of Screening for Prostate 
(ERSSP) and the Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial (PLCO) [72] yielded conflicting 
results regarding the utility of Prostate Specific Antigen 
(PSA)-based screening for prostate cancer, since PSA 
has not proved superior to digital rectal examination 
(DRE) [71, 73]. We cannot, however, exclude the possi-
bility that the introduction of more reliable biomarkers, 
such as MD-miniRNA, which could more effectively 
distinguish between prostatic hyperplasia and prostate 
cancer [74], will improve the efficacy of prostate cancer 
screening.
Further research and high-quality clinical trials are need-
ed. The introduction of new screening programs should 
be considered only after a careful Health Technology 
Assessment (HTA) has been performed, and in the light 
of solid clinical recommendations in conformity with 
Evidence-Based Medicine (EBM) [75, 76].
Future prospects and conclusions
In conclusion, prevention programs are an important 
weapon in the fight against cancer, and currently avail-
able evidence shows that they can contribute to reducing 
both the incidence of cancer and mortality. However, 
adherence to screening programs remains an issue to be 
addressed, in that screening tests are still underused [77]. 
A promising solution could be to personalize screening.
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Stratification for population-based risk-adjusted screen-
ing programs could be performed by using ad hoc risk 
models. Since cancer is indeed a common complex dis-
ease, screening programs could benefit from the use of 
genomic information, whilst this is generally not so help-
ful to diagnosis and prediction at the individual level [78].
It is anticipated that merging personal anamnestic data 
with those from clinical and radiological examinations 
will give rise to a new discipline, termed radiogenomics, 
which would optimize personalized medicine by corre-
lating imaging with genetic information [79].
Another scientific hint of the utility of “population-
based personalized screening” is the intrinsic biological 
and genetic difference between screening-detected can-
cers and interval cancers (that is to say, cancers arising 
during inter-screening intervals)  [79]. Genomics-based 
stratification could indicate the optimal screening inter-
val. For example, in the field of breast cancer screening, 
applying genomics and targeting subjects in the top 25% 
of the risk distribution would include approximately 
half of all future breast cancer cases [80]. Moreover, one 
mathematical model showed that a breast cancer screen-
ing program based on age and polygenic risk, and which 
targeted women aged 35-79 years, would reduce the 
number of false positives, and therefore of unnecessary 
biopsies and surgical procedures [81, 82].
In order to increase coverage, physicians should strongly 
recommend screening programs and discuss their patients’ 
doubts and perceived psycho-social barriers [83, 84]. Ad-
vocacy could play a major role, and Public Health profes-
sionals should discourage opportunistic screening. On the 
other hand, researchers should develop and investigate 
new, more acceptable, less invasive tests [37].
New information and communication technologies (IC-
Ts), such as smart-phone applications (known as apps), 
personalized short message services (SMS) and tex-
ting [85], could also help to promote adherence to pro-
grams. “Screening 2.0” is a great opportunity, which is 
still underused [86].
In sum, oncology has seen great changes in recent dec-
ades; together with improvements in diagnosis and treat-
ment, prevention has played a major role in reducing 
both the incidence of tumors and mortality. Advances in 
technology and social media and the discovery of new 
biomarkers are expected to bring additional benefits.
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